digoxin immune fab (ovine) (DigiFab) Report issue

Animal product Orphan Drug FDA Approved FDA
AACT DrugBank MeSH

Active Ingredient History

NOW
  • Now
Digoxin immune fab or digoxin-specific antibody is an antidote for overdose of digoxin. It is made from immunoglobulin fragments from sheep that have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind (GlaxoSmithKline) and DigiFab.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$2730.1300 - $3596.1700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

digibind | digidot | digifab | digitalis antitoxin | digoxin antibodies fab fragments | digoxin immune fab | digoxin immune fab (ovine) | digoxin immune fab, ovine | digoxin-specific antibody fragments | fabad | ovine digoxin immune fab

Organizations (9)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Atrial Fibrillation (approved 1986)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Acute Kidney Injury (Phase 4)

Bipolar Disorder (Phase 2)

Hypertension (Phase 4)

Pre-Eclampsia (Phase 2)

Renal Dialysis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue